tiprankstipranks
Trending News
More News >
Red Light Holland (TSE:TRIP)
:TRIP
Advertisement

Red Light Holland (TRIP) AI Stock Analysis

Compare
60 Followers

Top Page

TSE:TRIP

Red Light Holland

(OTC:TRIP)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative cash flows. Technical analysis provides some support with moderate strength, but valuation remains weak due to negative profitability metrics.

Red Light Holland (TRIP) vs. iShares MSCI Canada ETF (EWC)

Red Light Holland Business Overview & Revenue Model

Company DescriptionRed Light Holland Corp. engages in the production, cultivation, and sale of magic truffles to the recreational market in the Netherlands. It is also involved in the selection, distribution, and export of truffles, cannabidiol products, cannabis seeds, headshop products, cannabis bake house muffins, cookies, and cakes. The company sells its products under the iMicrodose and Maka brand name through 74 brick-and-mortar SmartShops, as well as through iMicrodose.nl and various other online stores across the Netherlands. Red Light Holland Corp. is based in Toronto, Ontario.
How the Company Makes MoneyRed Light Holland generates revenue primarily through the sale of magic truffles, which are cultivated and packaged for retail distribution. The company operates both direct-to-consumer sales through its online platform and wholesale transactions with retailers. Additionally, Red Light Holland explores partnerships with other companies in the psychedelics space, which can include joint ventures or collaborations on research and product development. Revenue is also supplemented by potential licensing agreements and educational initiatives related to psychedelic use, positioning the company as a thought leader in the industry.

Red Light Holland Financial Statement Overview

Summary
Red Light Holland faces significant financial challenges, with declining revenue and substantial losses. Negative profit margins and cash flow issues are concerning, despite a strong equity position. The company needs to improve profitability and cash flow generation.
Income Statement
35
Negative
Red Light Holland's income statement reveals significant challenges. The company has experienced negative revenue growth in the most recent year, with a decline of 7.94%. Margins are concerning, with a negative net profit margin of -81.75% and a negative EBIT margin of -83.54%, indicating substantial losses relative to revenue. Despite a gross profit margin of 38.69%, the overall profitability is heavily impacted by high operating losses.
Balance Sheet
45
Neutral
The balance sheet shows a relatively low debt-to-equity ratio of 0.13, suggesting conservative leverage. However, the return on equity is negative at -23.29%, reflecting the company's inability to generate profits from shareholder investments. The equity ratio stands at 81.76%, indicating a strong equity position relative to total assets, which provides some financial stability.
Cash Flow
30
Negative
Cash flow analysis highlights ongoing challenges, with negative operating cash flow and free cash flow. The free cash flow to net income ratio is 1.36, suggesting that the company is generating cash flow relative to its net losses. However, the negative free cash flow growth rate of -16.59% indicates deteriorating cash generation capabilities.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.94M4.94M4.75M3.95M2.33M110.96K
Gross Profit1.91M1.91M2.02M1.71M617.68K19.35K
EBITDA-3.59M-3.35M-6.58M-4.32M-8.55M-4.61M
Net Income-4.04M-4.04M-7.63M-5.40M-14.37M-1.64M
Balance Sheet
Total Assets21.22M21.22M24.08M30.14M32.94M36.30M
Cash, Cash Equivalents and Short-Term Investments12.27M12.27M14.17M18.53M26.62M32.78M
Total Debt2.18M2.18M1.72M1.77M1.50M866.50K
Total Liabilities3.87M3.87M3.82M3.80M3.78M2.24M
Stockholders Equity17.35M17.35M20.07M26.06M28.48M34.06M
Cash Flow
Free Cash Flow-2.01M-2.01M-3.92M-6.45M-5.28M-3.63M
Operating Cash Flow-1.48M-1.48M-3.23M-4.39M-4.88M-3.36M
Investing Cash Flow-525.40K-525.40K-650.43K-3.17M-582.74K-201.55K
Financing Cash Flow445.17K445.17K-206.95K-114.16K451.76K32.78M

Red Light Holland Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.04
Price Trends
50DMA
0.04
Negative
100DMA
0.03
Positive
200DMA
0.04
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
47.02
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.02 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
11.78M18.42-31.88%-1.14%0.00%
54
Neutral
11.16M4.330.40%22.41%0.00%
54
Neutral
9.07M-0.39-73.31%31.94%-45.55%
51
Neutral
11.48M-8.80-7.39%10.84%48.57%
46
Neutral
$16.49M-19.44%-8.27%50.55%
35
Underperform
5.29M-0.710.00%-46.59%9.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:TRIP
Red Light Holland
0.04
>-0.01
-12.50%
TSE:MVMD
Mountain Valley MD
0.02
-0.02
-50.00%
TSE:MPH
Medicure
1.14
0.06
5.56%
AVTBF
Avant Brands
0.59
-0.29
-32.95%
OILFF
Nextleaf Solutions
0.05
>-0.01
-16.67%
CLCFF
Christina Lake Cannabis
0.02
-0.02
-50.00%

Red Light Holland Corporate Events

Business Operations and StrategyProduct-Related Announcements
Red Light Holland Expands Safeway Partnership for Happy Caps
Positive
Sep 4, 2025

Red Light Holland’s subsidiary, Happy Caps Mushroom Farm, has expanded its partnership with Safeway, increasing its presence to 123 stores across Oregon and Washington State. This expansion, which represents an 86% increase in store count, is set to roll out in late fall and the holiday season of 2025, highlighting the growing consumer demand for functional mushroom products in the health and wellness market.

Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Red Light Holland Reports Q1 2026 Results and Strategic Initiatives
Neutral
Aug 28, 2025

Red Light Holland has reported its financial results for the first quarter of 2026, highlighting a decrease in revenue and gross profit compared to the previous year. Despite these challenges, the company has made strategic moves, including entering the U.S. retail market through Albertsons, launching new products like Health Canada-approved mushroom gummies, and investing in Bitcoin as a financial strategy. The company is also exploring M&A opportunities and remains optimistic about future growth in the psychedelic and functional mushroom sectors.

Business Operations and Strategy
Red Light Holland Advances Bitcoin Strategy with ETF Purchases and Trading Integration
Positive
Aug 26, 2025

Red Light Holland Corp. has announced progress in its Bitcoin balance sheet strategy by purchasing 10,600 shares of the iShares Bitcoin ETF and setting up infrastructure with a major exchange to leverage Arch Public’s algorithmic trading strategies. This initiative reflects the company’s commitment to integrating blockchain and cryptocurrency into its operations, aligning with its vision of innovation and long-term value creation in the psychedelics and wellness markets.

Business Operations and StrategyRegulatory Filings and Compliance
Red Light Holland Optimistic About Psilocybin Rescheduling Review
Positive
Aug 20, 2025

Red Light Holland Corp. has expressed optimism following the U.S. DEA’s decision to forward a psilocybin rescheduling petition to the Department of Health and Human Services for review. This move could potentially reclassify psilocybin from Schedule I to Schedule II, acknowledging its medical applications. Such a change would expand access to treatments for conditions like anxiety, depression, and PTSD, and facilitate research and development in the psychedelic sector. Red Light Holland, in partnership with Irvine Labs Inc., is advancing psychedelic research and has validated the potency of its psilocybin truffles for potential medical-grade applications.

Business Operations and StrategyProduct-Related Announcements
Red Light Holland Advances Medical Grade Psilocybin Development
Positive
Aug 18, 2025

Red Light Holland has received initial testing results from Irvine Labs, confirming the compatibility of its naturally derived psilocybin products with potential medical grade manufacturing processes. This development marks a significant step in their partnership, focusing on creating standardized psilocybin products for therapeutic markets, with Irvine Labs advancing proprietary dehydration and packaging processes to enhance product shelf life.

Business Operations and Strategy
Red Light Holland CEO to Highlight Blockchain-Psychedelics Synergy at Futurist Conference
Positive
Jul 30, 2025

Red Light Holland’s CEO, Todd Shapiro, will participate in the Blockchain Futurist Conference in Miami, highlighting the intersection of blockchain technology and psychedelics. This participation underscores the company’s commitment to decentralized finance, enhancing operational stability and growth, and promoting personal sovereignty by reducing reliance on traditional financial systems.

Business Operations and StrategyFinancial Disclosures
Red Light Holland Reports 2025 Financial Results and Strategic Growth
Positive
Jul 29, 2025

Red Light Holland has reported its 2025 audited year-end results, showcasing a strategic focus on fiscal discipline and growth in the psilocybin R&D sector. Despite a slight decrease in total cash balance and gross profit, the company achieved a reduction in EBITDA losses and maintained a diversified business model. Key achievements include partnerships with Costco Canada and Albertsons for the distribution of their Happy Caps products, as well as advancements in psilocybin research through collaborations with Irvine Labs and Arizona State University. These efforts position Red Light Holland for global growth and long-term profitability in the psychedelic sector.

Financial Disclosures
Red Light Holland to Release 2025 Year-End Results and Host Live Q&A
Neutral
Jul 28, 2025

Red Light Holland has announced the release of its 2025 audited year-end financial and operational results, which will be available prior to the market opening on July 29, 2025. Additionally, the company will host a live Q&A session with CEO Todd Shapiro and CFO Keith Li on July 30, 2025, to engage with shareholders and discuss the results, reflecting the company’s commitment to open dialogue with its stakeholders.

Business Operations and Strategy
Red Light Holland Partners with Arch Public for Strategic Bitcoin Acquisition
Positive
Jul 25, 2025

Red Light Holland has partnered with Arch Public Inc. to enhance its Bitcoin acquisition strategy, following the advice of cryptocurrency advisor Scott Melker. This collaboration aims to leverage Arch Public’s algorithmic trading platform to optimize Bitcoin purchases, supporting Red Light Holland’s financial resilience and innovation in decentralized finance. The partnership reflects Red Light Holland’s commitment to integrating blockchain and cryptocurrency into its operations, aligning with its strategy to hedge against market uncertainties and promote growth in the psychedelics sector.

Business Operations and StrategyExecutive/Board Changes
Red Light Holland Embraces Bitcoin Strategy with New Crypto Advisor
Positive
Jul 15, 2025

Red Light Holland has announced a strategic shift by integrating Bitcoin into its financial strategy, allocating up to C$2 million to Bitcoin and related assets. This initiative, led by newly appointed Lead Cryptocurrency Advisor Scott Melker, aims to enhance the company’s financial resilience and align with the decentralized ethos of the psilocybin and cryptocurrency communities. The move positions Red Light Holland as a pioneer in the psychedelics industry, diversifying its financial portfolio and potentially enabling Bitcoin payments for its brands, while also enhancing its credibility in the crypto space.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025